Current Atherosclerosis Reports

, Volume 11, Issue 1, pp 15–22

Is a statin as part of a polypill the answer?

Article

DOI: 10.1007/s11883-009-0003-0

Cite this article as:
Robinson, J.G. Curr Atheroscler Rep (2009) 11: 15. doi:10.1007/s11883-009-0003-0
  • 45 Views

Abstract

Statins are a necessary component of a polypill. Almost all patients have the potential to benefit from low-density lipoprotein cholesterol reduction with statins, although absolute benefits due to the reduction in coronary heart disease and stroke vary by risk level. The reduction in coronary heart disease and stroke from antihypertensive therapy is additive to the reduction in risk from statins. Used in combination with antihypertensive therapy, a moderate-dose statin would be expected to reduce cardiovascular risk by at least 50%, and a high-dose statin would be expected to reduce risk by at least 60% over an approximately 5-year period. A polypill containing aspirin in addition to a statin and antihypertensive therapy would be appropriate for most men over age 55 years, but not for high-risk women until age 65 years and moderately high-risk women until age 75 years. Polypills in development hold great promise for reducing the global burden of cardiovascular disease.

Copyright information

© Current Medicine Group LLC 2009

Authors and Affiliations

  1. 1.Departments of Epidemiology & Medicine, Lipid Research ClinicUniversity of IowaIowa CityUSA